Blockbuster Drugs Create, Develop and Market a Billion Dollar Drug 2007-2012

- Do you know what the next major blockbuster will be?

- In the year 2000, when visiongain first produced their Blockbuster Drug market report there were 55 blockbuster drugs – now there are over 100.

This unique in-depth management report examines the future prospects for blockbuster drugs from 2007-2012. It delivers direct to you future sales forecasts for leading pharmaceutical blockbuster products. In 2006, there were over a hundred of those high revenue generating drugs in the global market. This detailed report also highlights pipeline developments, potential blockbusters on the market and important contemporary issues, especially commercial drivers and restraints. By reading this report you will be able to spot a potential blockbuster before your competitors.

Blockbusters – drugs with $1 billion annual sales or more - constitute the “backbone” of the pharmaceutical industry, providing high revenue streams over relatively long periods. All the major pharmaceutical companies depend heavily upon blockbuster products. In that manner, leading companies underpin their corporate presence, influence and branding, high revenue flows, profitability and attractiveness to investors. Furthermore, specialised companies – especially in biotechnology – are increasingly involved with blockbuster and potential blockbuster products, both directly and as commercial partners.

By drawing on detailed profiles of current blockbusters, best practice in product launch and sales protection in the face of patent expiry can be identified; this report delivers the leading information on how you and your company can ensure its next blockbuster drug.

However, the report indicates that Blockbuster revenues achieved in recent years will become increasingly difficult to sustain and to re-create during the years ahead. Current and potential blockbuster revenues are seriously threatened by patent expiry, regulatory hurdles, reduced R&D efficiency, increasing competition, formidable therapeutic challenges and healthcare payers influencing pricing. Nevertheless, there are strong drivers of growth including unmet therapeutic needs, rising incidence of many diseases, aging populations, rising living standards and fast-developing geographical markets. The future of current and potential blockbusters is therefore vitally important to all companies in the pharmaceutical sector, especially in this uncertain period of economic changes and pressures.

The Blockbuster Drug Market 2007 examines the global blockbuster market critically through a comprehensive review of available information. Sources include industrial databases, commercial news, published reports, economic research and consultation with experts. Visiongain applies financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion.

In particular, Blockbuster Drug Market 2007 concentrates on the following essential aspects of the market:

• Analysis and in-depth breakdowns of the current blockbuster market

• Forecast of the worldwide pharmaceutical market from 2007-2012

• Opinionated assessments of the drivers and restraints facing blockbusters

• How to take advantage of the opportunities and overcome the threats facing blockbusters

• Growth of the blockbuster sector between 2006-2012 by market segment

• Commercial prospects for the market-leading drugs, with sales forecasts from 2007-2012

• The potential of generics manufacturers to penetrate this market

• Pipeline developments with blockbuster potential

• Currently marketed drugs with blockbuster potential

• Analysis of un-met/under-met therapeutic needs and relative advantages of products that would lead to blockbusters

Why you must buy this report:

• To benefit from the leading analysis of the prospects for blockbuster drugs and how to develop them

• To discover predicted revenues, growth rates and other key metrics for leading pharmaceutical treatments from 2006-2012

• To determine key activities of your leading competitors as they try to develop blockbuster drugs

• To discover “hot” pipeline developments and up-and-coming products

• To determine the forces that influence the market for blockbuster products:

• Competitive characteristics of the market

• Drivers

• Restraints

• Strengths, weaknesses, opportunities and threats

• To ensure you remain at the forefront of the blockbuster market - both technologically and commercially

This visiongain report is the single tool to equip you with the latest trends in all regional markets and why all (stakeholders) demand a new generation of profitable blockbuster drugs. This report will arm you with all you and your company require to develop, price, launch and market a blockbuster drug.

Unique benefits to you when you order this report:

- Primary research throughout. You will not find this information anywhere else

- Report stored in your reading room for ever

- Full searchable report when you buy the company or corporate editions

- Copies can be printed off for offline reading

- Packed with charts, analysis, figures, graphs and tables

You should read this report today. Contact me know to order your copy.

PRICING

- Departmental copies (this entitles up to 5 individual users in your department) of this report are available for only $5,998.00. This is not suitable for library usage.

- Allow your whole company to have access to this information for only $9,998.00. Company-wide License allows your whole company access and intranet use on CD Rom and .pdf. Suitable for library storage and use.

- Does your company have over 2,500 employees? Have the whole company access this information for a special rate of only $13,998.00

November 2007

Table of Contents

Price
Department Licence 5 Users $5,998.00
Company-wide Intranet Licence $9,998.00
Over 2500 employees $13998.00